– USA, CA – Anivive Lifesciences, a technology-driven pet pharmaceutical company, today announced the appointment of Jim Beaubien to its Board of Directors, bringing over 30 years of P/E, IPO, and M&A experience to the board.
“We are extremely excited about the addition of Jim to our Board. He was Anivive’s first investor and truly understands our business and where we are headed. I am confident that with his experience, the best days for Anivive lie ahead,” said CEO Dylan Balsz.
About Jim Beaubien
Jim Beaubien is the former Latham and Watkins Office Managing Partner. During his 30+ years at Latham & Watkins, Jim Beaubien Chaired the Corporate Department and played a pivotal role in growing the partnership into the largest law firm in the world. He was counsel to top Fortune 500 companies, some of which include: Live Nation, Cerner Corporation, DaVita, Mattel, Health Net, Crown Resorts, Farmer Bros., Kilroy Realty, and Moelis & Co.
“I remember when Dylan first approached me on the idea of repurposing human therapeutics for pets,” said Jim Beaubien, “What he and the team have done has been spectacular. From their conditional FDA approval for a canine lymphoma treatment to their upcoming Valley Fever Vaccine, I am extremely excited to join the board and contribute to the next chapter of the Anivive journey.”
About Anivive Lifesciences
Anivive is a pet pharmaceutical company at the intersection of biotech, AI, software, and veterinary medicine. Our proprietary software platform accelerates the development of new, affordable treatments for life-threatening diseases in pets. Anivive’s pipeline includes 8+ first-in-class therapeutics for three critical areas: Oncology, Anti-Virals, and Anti-Fungal Vaccines.
For more information: https://www.anivive.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
